BIOLIGN Conference Singapore 2026
【Registration Notice】This form is for pre-registration purposes only; submission does not guarantee successful registration. Final registration is subject to the payment notice and confirmation letter issued by the organizing committee. Please provide accurate information above.
About the Conference
Following the successful hosting of BIOLIGN Conference Guangzhou 2026 on May 19–20, BIOLIGN will arrive in Singapore on November 18–19, 2026, bringing together BIOLIGN Conference Singapore 2026.
Leveraging Singapore’s strategic position as a key life sciences hub connecting Southeast Asia and the global biopharmaceutical ecosystem, the conference will further connect innovative drug development resources across China, Singapore and the wider Asia-Pacific region, fostering cross-regional industry exchange, technology collaboration and international business expansion.
The Singapore conference will continue to embrace the theme of:
“Accelerating New Medicines Towards Global Markets”
Positioned in Singapore and serving the Asia-Pacific region, the conference will focus on key areas including:
Next-generation innovative therapies
Global partnerships and Asia-Pacific market expansion for innovative medicines
Global clinical development
CMC, process development and commercialization
RNA and nucleic acid therapeutics
Cell and gene therapy (CGT) and emerging therapeutics
Small molecule therapeutics and targeted protein degradation
The event will bring together 50+ expert speakers, 500+ professional delegates, and 150+ innovative pharmaceutical companies, Biotech companies, research institutions and key ecosystem partners.
Through keynote presentations, focused sessions, panel discussions, project showcases and business networking opportunities, the conference will promote deeper connections across key areas including drug discovery, clinical development, process development, manufacturing and global partnerships.
From Guangzhou to Singapore, BIOLIGN will further strengthen connections between China, Southeast Asia and the broader Asia-Pacific markets, bringing together pharmaceutical companies, Biotech companies, research and clinical institutions, CRO/CDMO organizations, process and manufacturing technology platforms, and industry partners across Singapore and neighboring markets.
By facilitating collaboration between innovation resources, industrial capabilities and international partnership opportunities, BIOLIGN aims to accelerate the advancement of high-value innovations into Asia-Pacific and global markets.
On behalf of the BIOLIGN Conference Singapore 2026 Organizing Committee, we sincerely invite you to join this premier gathering and engage with leading professionals from the global biopharmaceutical community to explore new opportunities in innovative drug development, commercialization and international collaboration.